secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001104659-22-037111
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

APAC to merge with Ligand's OmniAb antibody discovery business at $850M valuation
--------------------------------------------------------------------------------

- Pre-money equity valuation of $850M; minimum $130M gross cash to combined company, up to $266M.
- Avista commits up to $115M ($15M PIPE + $100M backstop); Ligand contributes $15M.
- Ligand shareholders to own 75-84% of combined firm; APAC shareholders ~20%, Avista ~5%.
- Transaction expected to close H2 2022; OmniAb to list on Nasdaq as 'OABI'.
- Matt Foehr named CEO of OmniAb; Kurt Gustafson appointed CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000110465922037111/0001104659-22-037111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000110465922037111/tm2210239d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-037111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer